Corticosteroids are first-line therapies for the treatment of many inflammatory dermatoses, including atopic dermatitis, contact dermatitis, psoriasis and seborrheic dermatitis. Desonide, a low-potency corticosteroid, has been formulated in a moisturizing hydrogel that has been US FDA approved for mild-to-moderate atopic dermatitis in patients as young as 3 months of age. This new formulation represents a safe and effective option for atopic dermatitis patients and provides the benefits of a novel hydrogel vehicle that is both a well-tolerated and a cosmetically elegant alternative to traditional vehicles.
No takes yet. Share an insight, caveat, or question.
Gelbard et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: